For dogs of any size or shape, use VETMEDIN at the first clinical signs of CHF.

VETMEDIN is now available in 4 dosage sizes to fit each dog’s individual needs.

- 1.25 mg (2x day)
- 2.5 mg (2x day)
- 5 mg (2x day)
- 10 mg (2x day)

VETMEDIN is recommended for use at the onset of clinical signs of CHF.1

Both the QuESt and VetSCOPE studies were completed using VETMEDIN Capsules. In the US, only the chewable tablets are licensed. Both the capsules and chewable tablets are recommended for use at the onset of clinical signs of CHF.1

Important safety information: VETMEDIN should not be given in case of hypertrophic cardiomyopathy, no structural abnormality or murmur. It is not indicated for dogs with valve disease receiving pimobendan or benazepril: the QuESt study.2

Significant improvement in key clinical signs:3*

- 74% of VETMEDIN-treated dogs were free of signs after 8 weeks compared with 29% on an ACE inhibitor (P=0.0071)
- Structural abnormality but no clinical signs of heart failure
- Structural abnormality but current or previous clinical signs of heart failure
- Clinical signs of heart failure refractory to standard treatment

VETMEDIN improves QOL and helps dogs with CHF feel better.1

- 91% longer survival time in VETMEDIN-treated dogs
- 267 days compared with 140 days (P=0.0071)
- Use only in dogs with clinical evidence of heart failure. For additional information, see the full prescribing information enclosed.

VETMEDIN is proven to lengthen life with few adverse events.1

- Use VetMedin here
- Two 10 mg in morning and evening
- Lucky, 22 lb
- Daily dose: 1.25 mg in the morning and 1.25 mg in the evening
- Simon, 122 lb
- Daily dose: 25 mg in the morning and 25 mg in the evening
- Clyde, 65 lb
- Simon, 120 lb
- Daily dose: 2.5 mg in the morning and 2.5 mg in the evening

Important safety information: The safe use of VETMEDIN has not been established in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with clinical evidence of heart failure. For additional information, see the full prescribing information enclosed.
**QuESt** study

† Survival was defined as the composite endpoint of cardiac death, euthanasia due to heart failure, or treatment failure. All dogs received furosemide therapy.

* Both the QuESt and VetSCOPE studies were completed using VEtMEDIN Capsules. In the US, only the chewable tablets are licensed. Both the capsules and chewable VETMEDIN is recommended for use at the onset of clinical signs of CHF.1

**Important safety information:**

VETMEDIN is available for your client’s convenience in 1.25 mg, 2.5 mg, 5 mg, and 10 mg dosage sizes. These additional dosing options will help owners choose that are both effective and cost-effective.

**Think VETMEDIN from the start and make it the heart of your treatment plan.**

For more information, contact your Boehringer Ingelheim sales representative or visit www.vetmedin.com.

Important safety information: The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with clinical evidence of heart failure. For additional information, see the full prescribing information enclosed.

ACVIM guidelines

VETMEDIN is recommended for use at the onset of clinical signs of CHF.1

**VETMEDIN improves QOL and helps dogs with CHF feel better.**

74% of VETMEDIN-treated dogs were free of signs after 8 weeks compared with 29% on an ACE inhibitor (P=0.0071).

**VETMEDIN is proven to lengthen life with few adverse events.**

91% longer survival time in VETMEDIN-treated dogs 267 days compared with 140 days on an ACE inhibitor (P=0.0099).

**Use VETMEDIN here**

ACVIM guidelines

**Important safety information:**

VETMEDIN should not be given in case of hypertrophic cardiomyopathy, or structural abnormality but no clinical signs of heart failure and clinical signs of heart failure and previous clinical signs of heart failure or dilated cardiomyopathy. Use only in dogs with clinical evidence of heart failure. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian.


VETMEDIN is now available in 4 dosage sizes to fit each dog’s individual needs.

**For Dogs of Any Size or Shape, Use VETMEDIN at the First Clinical Signs of CHF.**

VETMEDIN is available in 1.25 mg, 2.5 mg, 5 mg, and 10 mg dosage sizes. These additional dosing options will help you ensure accurate dosing, encourage ongoing compliance, give owners choices that are both effective and cost-effective.

Think VETMEDIN from the start and make it the heart of your treatment plan. For more information, contact your Boehringer Ingelheim sales representative or visit www.vetmedin.com.

Important safety information: The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with clinical evidence of heart failure. For additional information, see the full prescribing information enclosed.

**ADD LIFE. BECAUSE EVERYONE DESERVES MORE MOMENTS LIKE THIS.**

Don’t wait to prescribe VETMEDIN to see the difference it can make for dogs with CHF.

VETMEDIN is now available in 4 dosing sizes to fit each dog’s individual needs.

**VETMEDIN is a recommended by the ACVIM as part of standard treatment for dogs with CHF.**2

Well-known clinical studies have established that VETMEDIN can help dogs with CHF feel better and live longer.2

The QUEST study update showed that dogs treated with VETMEDIN required less therapy to maintain quality of life (QOL) than those treated with an ACE inhibitor.2

**VETMEDIN improves QOL and helps dogs with CHF feel better.**

 Logical improvement in key clinical signs:3*

Significant improvement in key clinical signs:3*

Were free of signs of VETMEDIN-treated dogs 74% compared with 29% on an ACE inhibitor (P=0.0011).

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN improves QOL and helps dogs with CHF feel better.3
ACT NOW. TREAT CHF WITH VETMEDIN AND PRESERVE QOL WITH LESS THERAPY.  

**QUEST study update:** Dogs on VETMEDIN required less therapy to maintain QOL than dogs on an ACE inhibitor.  

In contrast to VetSCOPE, which measured changes in QOL, the QUEST study focused on extending survival time so intensification of therapy was permitted.  

VETMEDIN also improved body temperature, serum sodium concentration, total protein concentration, and packed cell volume, while reducing fluid retention.  

Please refer to the package insert enclosed.

**QUEST study update:** VETMEDIN demonstrated a variety of clinical advantages.

| VETMEDIN-treated dogs had significantly longer time to intensification of therapy |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| **VETMEDIN**                    | **ACE INHIBITOR**               |
| 98 (30–276)                     | 59 (11–121)                     |
| P=0.0008                         |                                 |

5.69 times more likely to intensify treatment first (P=0.0008).  

Dogs that were NOT given VETMEDIN required more frequent administration of additional medications to maintain a similar QOL.

VETMEDIN-treated dogs had less cardiac enlargement after therapy as demonstrated by significantly lower median vertebral heart score.  

In dogs that were NOT given VETMEDIN, heart size continued to enlarge further beyond normal range.

VETMEDIN also improved body temperature, serum sodium concentration, total protein concentration, and packed cell volume, while reducing fluid retention.  

Please refer to the package insert enclosed.
VETMEDIN is recommended for use at the onset of clinical signs of CHF.1

VETMEDIN is now available in 4 dosage sizes to fit each dog's individual needs.

Use VETMEDIN from the start to help dogs with CHF live longer.2

VETMEDIN improves QOL and helps dogs with CHF feel better.3

VETMEDIN is proven to lengthen life with few adverse events.4

VETMEDIN is available for your client's convenience in 1.25 mg, 2.5 mg, and 10 mg dosage sizes. These additional dosage options will:

- Help you ensure accurate dosing
- Encourage ongoing compliance
- Give owners choices that are both effective and cost-effective

Think VETMEDIN from the start and make it the heart of your treatment plan.

For more information, contact your Boehringer Ingelheim sales representative or visit www.vetmedin.com.

Important safety information: The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. Use only in dogs with clinical evidence of heart failure. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. Side effects should occur, pet owners should contact their veterinarian.

Important safety information: The safety of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. Use only in dogs with clinical evidence of heart failure. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. Side effects should occur, pet owners should contact their veterinarian.

VETMEDIN is recommended by the ACVIM as part of standard treatment for dogs with CHF.1

Well-known clinical studies have established that VETMEDIN can help dogs with CHF feel better and live longer.2

The QUEST study update showed that dogs treated with VETMEDIN required less therapy to maintain quality of life (QOL) than those treated with an ACE inhibitor.2

For dogs of any size or shape, use VETMEDIN at the first clinical signs of CHF.

VETMEDIN is available in 4 dosage sizes to fit each dog's individual needs.

VETMEDIN is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, New York, New York. © 2014 Boehringer Ingelheim Vetmedica, Inc. VET0114015 www.vetmedin.com For more information, contact your Boehringer Ingelheim sales representative or visit www.vetmedin.com.